Imbruvica will be used to treated mantle cell lymphoma.
Pondering next steps for Sarepta and its Duchenne muscular dystrophy drug eteplirsen.
Sarepta will need to conduct a larger phase III study before seeking eteplirsen approval for Duchenne muscular dystrophy.
Three press releases on Ampion, but investors still can't determine if the drug is effective.
Shire's acquisition centers around Viropharma's Cinryze, which treats hereditary angioedema.
Marc Beer's suggests Juxtapid helps patients live longer, but FDA says the drug does no such thing.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Gazya is expected to replace Roche's current blockbuster Rituxan as a treatment for many blood-related cancers.
Gerons imetelstat might be the first myelofibrosis drug to treat the underlying cause of the disease, but it's not without controversy.
A Malaysian real estate developer with no healthcare experience is going to sell Cytori's stem-cell therapies in Asia.